{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:08:05Z","timestamp":1780412885193,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.urology.2017.01.018","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T06:30:21Z","timestamp":1486103421000},"page":"149-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non\u2013muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Gu\u00e9rin Therapy"],"prefix":"10.1016","volume":"103","author":[{"given":"Dennis J.","family":"Robins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Matulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashed","family":"Ghandour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Joel","family":"DeCastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2017.01.018_bib0010","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2017.01.018_bib0015","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0020","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","article-title":"Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup","volume":"147","author":"Herr","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0030","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)49690-X","article-title":"Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer","volume":"132","author":"Morales","year":"1984","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0045","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0050","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0055","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.eururo.2014.11.043","article-title":"Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial","volume":"67","author":"Bochner","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0060","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eururo.2013.01.010","article-title":"Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium","volume":"64","author":"Johar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0065","first-page":"141","article-title":"Taxol: a history of pharmaceutical development and current pharmaceutical concerns","volume":"15","author":"Adams","year":"1993","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.urology.2017.01.018_bib0070","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","article-title":"Taxol: a novel investigational antimicrotubule agent","volume":"82","author":"Rowinsky","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2017.01.018_bib0075","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2017.01.018_bib0080","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2017.01.018_bib0085","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2017.01.018_bib0090","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/ecp.11.7","article-title":"Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review","volume":"4","author":"Montero","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.urology.2017.01.018_bib0095","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","article-title":"A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0100","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0105","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2017.01.018_bib0110","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0115","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","article-title":"The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience","volume":"27","author":"Barlow","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0120","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0125","doi-asserted-by":"publisher","first-page":"656918","DOI":"10.1155\/2015\/656918","article-title":"The role of interferon in the management of BCG refractory nonmuscle invasive bladder cancer","volume":"2015","author":"Correa","year":"2015","journal-title":"Adv Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0130","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0135","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0140","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0145","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","article-title":"Treatment options available for bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer","volume":"62","author":"Yates","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2017.01.018_bib0150","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429517300468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429517300468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T02:52:23Z","timestamp":1568775143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429517300468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":29,"alternative-id":["S0090429517300468"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2017.01.018","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non\u2013muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Gu\u00e9rin Therapy","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2017.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}